International Alfapump Cohort Study

International Alfapump Cohort Study: in Patients With Refractory Ascites Due to Liver Cirrhosis or Malignant Ascites With a Life Expectancy of 6 Months or Less

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.

In a real-world setting, all patients implanted with an alfapump system according to it's intended use, not participating in another clinical study in which the alfapump is studied.

Inclusion Criteria:

• All patients implanted with an alfapump are eligible for this registry

Exclusion Criteria:

• Patients younger than 18 years
• Pregnancy
• Inability to operate the Smart Charger to recharge the alfapump
• Participating in another study in which the alfapump is studied